New Insights on CAB Gel Performance Across Diverse Acne Demographics
This is a must-read article from the Journal of Drugs in Dermatology (JDD) that every practicing clinician will want on their radar.
Managing moderate-to-severe acne often requires a tailored approach, particularly when considering how patient age and sex influence treatment response and tolerability. As the first fixed-dose, triple-combination topical therapy for acne, clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% (CAB) gel has already generated significant interest across the dermatology community for its robust efficacy profile.
A newly published post hoc analysis dives deeper into clinical trial data to evaluate how CAB gel performs across distinct patient subgroups. Researchers pooled findings from one phase 2 and two phase 3 double-blind, randomized, 12-week trials to examine outcomes specifically segmented by age and sex. The analysis evaluated response rates and safety outcomes among younger females, older females, younger males, and older males using once-daily CAB gel compared to vehicle.
The findings offer valuable clinical clarity for dermatology providers treating diverse patient populations in daily practice. Across all evaluated subgroups, CAB gel consistently demonstrated strong efficacy outcomes and a safety profile consistent with the broader clinical trial population.
Whether you are managing adolescent acne or adult female patients, these subgroup results provide critical evidence on treatment success and lesion reduction rates. Discover the specific numerical data, statistical significance across demographics, and complete safety findings by reviewing the full study details today.
Blog write-up assisted by AI
